Pinobio Wins National ADC Project Grant... 5 Billion KRW Support
Pinobio, a bio company specializing in antibody-drug conjugate (ADC) platforms and targeted anticancer drugs, announced that it has been selected as the lead research and development institution for a national project under the Bioindustry Technology Development Project supported by the Ministry of Trade, Industry and Energy. Accordingly, Pinobio will receive approximately 5 billion KRW in government funding over the next five years to develop GMP production manufacturing processes for excellent ADC pharmaceuticals and quality control standards.
The project to be undertaken is the development of high-quality ADC customized manufacturing process technology based on fusion technology among personalized diagnostic and therapeutic products. Through this project, Pinobio plans to develop the GMP production process for the trophoblast cell-surface antigen (TROP)-2 ADC, which it is currently developing in-house. Pinobio will receive support for candidate selection of TROP-2 ADC, securing core materials and manufacturing process technologies such as target antibodies, payloads, and linkers, development of ADC scale-up processes and standard product production, as well as development and optimization of ADC lyophilized formulations.
This project will be carried out in collaboration with Osong Advanced Medical Industry Promotion Foundation (K-BioHealth). K-BioHealth is a public institution under the Ministry of Health and Welfare and possesses the domestic mother cell bank K-Bio-K1. Both parties plan to cooperate comprehensively in developing GMP-grade ADC production manufacturing processes, including the development of production cell lines applying these cells.
The Bioindustry Technology Development Project is a national support program aimed at fostering future new industries and enhancing the industrial competitiveness of core industries by intensively supporting the development of core and foundational technologies in the bio sector based on the national growth strategy. A total of 18 projects have been selected and supported across four areas: personalized diagnostic and therapeutic products, digital healthcare, advanced bio-new materials, and human microbiome pharmaceutical product commercialization support.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Jung Doo-young, CEO of Pinobio, said, “Winning this large-scale national project with an investment of 5 billion KRW over five years will greatly aid the progress of our TROP-2 ADC research and development.” He added, “We will closely collaborate with K-BioHealth not only to enhance the completeness of our ADC platform technology but also to contribute to securing domestic ADC production technology.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
